NOVARTIS

Pfizer's IBRANCE, a CDK4/6 inhibitor, extended progression-free survival by 15 months in metastatic breast cancer patients when combined with anti-HER2 therapies. IBRANCE, initially approved in 2015, is the first treatment of its kind to show benefit in HR+, HER2+ metastatic breast cancer.

Monte Rosa Therapeutics appoints Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes, currently EVP, Global R&D and CMO of Teva Pharmaceuticals, brings extensive biopharmaceutical experience. Monte Rosa develops molecular glue degrader (MGD) medicines, leveraging its QuEEN discovery engine for oncology, autoimmune, and inflammatory diseases.

The global pancreatic cancer market is projected to grow from USD 3.1 billion in 2023 to USD 11.5 billion by 2033, driven by advancements in precision medicine, novel chemotherapy combinations, and emerging immunotherapies. Key trends include targeting KRAS mutations, reevaluating growth factors like G-CSF, and innovations in diagnostic technologies and gene-editing. Despite challenges, ongoing research and drug approvals offer hope for improved patient outcomes.

Parkinson's disease market to grow at 5.8% CAGR (2020-2034) due to advancements in diagnostics, increased awareness, and a rising number of cases. Emerging therapies like Supernus/Britannia's SPN-830, AbbVie's tavapadon, and Pharma Two B's P2B001 could significantly impact market dynamics. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size (2020-2034) for 7MM.

Hosts discuss PARASOL Initiative's efforts to establish surrogate endpoints for FSGS trials, focusing on proteinuria as a robust predictor of kidney failure, potentially enabling smaller, faster trials.

Gene therapy market to reach $5.3 billion by 2028 with a CAGR of 19.8%. Key players include Novartis AG, Orchard Therapeutics, Celgene, Spark Therapeutics, Gilead Sciences, and Sibiono GeneTech. Market driven by genetic disease prevalence, tech advancements, and R&D investments. Challenges include high costs, manufacturing complexities, ethical concerns, and skill shortages. Future trends include CRISPR adoption, personalized medicine, and non-viral delivery systems.

Pfizer's Ibrance showed efficacy in HR+, HER2+ metastatic breast cancer, extending median progression-free survival by 50% in Phase III PATINA trial. This marks the first benefit shown by a CDK4/6 inhibitor in this patient group, representing about 10% of breast cancers. Ibrance, first approved in 2015, generated $4.75 billion in 2023, while Novartis' Kisqali brought in $2.08 billion.

Novartis partners with PTC Therapeutics to develop PTC518, a small molecule therapy targeting the root cause of Huntington’s disease, offering potential disease-modifying treatment. The therapy is in Phase II trials, with Novartis assuming global commercialisation responsibilities upon trial completion.

COVID-19 treatment companies focus on vaccines, antivirals, monoclonal antibodies, and supportive care. Vaccines like Pfizer-BioNTech and Moderna reduce severe cases, while antivirals like Remdesivir and Paxlovid limit viral replication. Monoclonal antibodies like Bamlanivimab offer early intervention. Supportive care remains crucial. Market growth is driven by COVID-19 spread, new variants, and increased demand for effective therapies. Government investments and rapid vaccine advancements accelerate treatment availability. The global pulmonary drug delivery systems market is projected to reach USD 97.8 billion by 2033.

The PARASOL Initiative aims to revolutionize FSGS drug development by validating proteinuria as a therapeutic endpoint. Experts discuss how proteinuria reduction can accelerate approvals, emphasizing the need for addressing podocyte dysfunction. The initiative also focuses on specimen banking for biomarker discovery and collaborative research models for rare kidney diseases.